RNA Outsourcing Resources

  1. Delivering The Promise Of Gene Therapy 1/22/2024

    Gene therapies rely on efficient, precise methods of delivering genetic material. Examine how combining polymeric nanoparticles with CRISPR therapies is increasing the potential for improved treatment.

  2. Pre-Banking And Avoiding Manufacturing Challenges For GMP Plasmids Containing Unstable Sequence Regions 4/21/2021

    Ensuring consistent replication and proper retention of plasmid DNA sequence is vital to the economics and efficiency in generating starting materials used for production of AAV delivered gene therapy and mRNA vaccines and therapeutics.

  3. Reducing Lead Time, Delivering >99.5% OTIF 1/23/2024

    Explore the stocking solution offered to a mid-sized CDMO in need of a high volume of safety stock inventory to support their customer portfolio growth.

  4. The Current And Future Value Of mRNA Vaccines And Therapeutics 2/4/2026

    Discover how decades of research have propelled mRNA technology to the forefront of therapeutic development and learn how our expertise is advancing mRNA drug development.

  5. Cell And Virus Banking In OV Development And Manufacturing 5/14/2024

    Delve into the exciting potential of OVs, including the critical role of cell and virus seed banks, and discover key considerations for establishing cell and virus banks for OV production.

  6. Consolidating The Supply Chain For mRNA 2/12/2024

    Learn about the first end-to-end cGMP facility that was developed for mRNA manufacturing to address the shortage of CDMOs and the inadequate and inefficient supply chain options for sourcing GMP mRNA.

  7. How To Choose The Right CRO For Your Clinical Trial 3/28/2025

    Selecting the right Contract Research Organization (CRO) is critical for the success of a clinical trial. This article outlines essential factors to consider during the selection process.

  8. Accelerate LNP Manufacturing With Automated Process Development 2/5/2026

    Manual LNP formulation introduces process variability that threatens particle quality and yield. As programs scale toward clinical production, maintaining strict control over CQAs becomes essential.

  9. Addressing Challenges In mRNA Drug Development And Manufacturing

    mRNA-based drug products serve as an ideal platform for use in infectious disease, protein replacement, and immuno-oncology applications due to the simplicity of manufacturing and robust immune response.

  10. Scaling Manufacturing Flexibility For Fill-Finish Commercial Success 2/5/2026

    Pharma and biotech developers rely on adaptable fill‑finish capacity to meet evolving market demands, scale products from clinical to commercial, and respond rapidly to public‑health emergencies.